Vertex Pharmaceuticals price target raised to $520 from $460 at Truist
Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on the shares. The firm is positive on the launch of Journavx, which is seeing “broad ...
Healthcare Dive22h
A new, non-opioid pain drug is here. Getting it to patients could be agony.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
FiercePharma1d
Vertex lays out plan to increase access and launch non-opioid pain reliever Journavx
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
BioPharma Dive1d
Vertex COO Arbuckle to step down later this year
Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...
Vertex projects $11.75B-$12B 2025 revenue with new launches driving growth
Q4 2024 Management View CEO Reshma Kewalramani highlighted the planned leadership transitions, with Stuart Arbuckle retiring in July 2025. Charlie Wagner will take on additional responsibilities as ...
Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
fingerlakes14d
FDA approves first new non-opioid painkiller in 20 years
The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...
LocalSYR4d
Newly FDA-approved non-opioid painkiller is first of its kind in over 20 years
For the first time in 20 years, the Food and Drug Administration has approved a new pharmaceutical approach to treating pain. On January 31, the FDA approved Journavx as ...
BioSpace5d
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
South Boston Online5d
Important New VERTEX Painkiller Is Approved
By Rick Winterson  Vertex Pharmaceuticals is a worldwide biotechnology corporation. It was founded 35 years ago in Cambridge.  It has now established its global headquarters on Fan Pier in South ...
News on 65d
New non-opioid drug offers hope for pain management
Journavx, a new non-opioid pain medication, offers a safer alternative for managing acute pain while reducing the risk of ...
CenExel Celebrates FDA Approval of JOURNAVX(TM), a Groundbreaking Non-Opioid Pain Treatment
CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...